Elyse Rafal is a Dermatology physician affiliated with DermResearch. OpenAlex indexes 23 publications with 1,431 citations (h-index 15); ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2500 Route 347
Building 22a
Stony Brook, NY 117902555
Telephone
631-689-0300Registry record last updated 9 Jun 2008.
Clinical trials
- Saypha® VOLUME Lidocaine for Midface Augmentation
Sponsor: Croma-Pharma GmbH
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
35 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Arcutis Biotherapeutics, Inc.Program year202513 payments
- SUN PHARMACEUTICAL INDUSTRIES INC.Program year202515 payments
- Janssen Scientific Affairs, LLCProgram year20253 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
61%Azole Antifungal39.4%Ketoconazole100%Part D≥26 patientsLincosamide Antibacterial14.1%Clindamycin Phosphate100%Part D≥15 patients+ 1 more class in this area
Dermatology
26.1%Corticosteroid6.2%Triamcinolone acetonide100%Part B, office-administered≥12 patientsOther antifungals for topical use6.2%Ciclopirox100%Part D<11 patients+ 3 more classes in this area
Respiratory
8.3%RNA Synthetase Inhibitor Antibacterial8.3%Mupirocin100%Part D≥13 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Correction: Trifarotene Reduces Risk for Atrophic Acne Scars: Results from A Phase 4 Controlled Study
Dermatology and Therapy
2024 - Trifarotene Reduces Risk for Atrophic Acne Scars: Results from A Phase 4 Controlled Study
Dermatology and Therapy
2023 - Risque cicatriciel dans l’acné et trifarotène 50 μg/g : résultat d’une étude randomisée, en double-aveugle (START)
Annales de Dermatologie et de Vénéréologie - FMC
2023 - Dermatological Adverse Events Associated with Topical Brimonidine Gel 0.33% in Subjects with Erythema of Rosacea: A Retrospective Review of Clinical Studies.
PubMed
2015
Similar KOLs
Other experts from the same institution or the same specialty.
Hywel C Williams
University of Nottingham
Mohsen Afarideh, MD, MPH
Mayo Clinic
Brigitte Dréno
Centre National de la Recherche Scientifique
Giovanni Damiani
University of Milan
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”